The tumor modeling industry is abuzz, with Merck’s acquisition of HUB organoids, Takeda's expanded collaboration with Tempus to utilize biologically relevant models, and the FDA Modernization Act 3.0 promoting reduced animal use. Yet, with cancer drugs translating to the clinic at only ~5% and clinical trial failure rates rising, the need to invest in more predictive models to de-risk candidate development has never been greater.

Built by biopharma, for biopharma, the 13th Tumor Models Summit Boston returns to bring together 180+ East Coast tumor modeling experts from pharma, biotech, and preclinical CROs, to enable you to stay abreast of confidently implementing reproducible and predictive oncology models to successfully bridge the translational gap with optimized efficiency, and cost-effectiveness.